Celestra Health Systems

Celestra Health has developed an AI-driven wearable platform that uses smart insoles to collect real-world gait data from patients with neurological conditions. The system provides early detection of disease progression by analyzing walking patterns via a HIPAA-compliant cloud infrastructure. Clinical trials across four countries have shown strong results for both usability and sensitivity in detecting changes related to multiple sclerosis and Parkinson’s disease. The company received FDA Class II medical device certification in late 2024, enabling commercial sales to clinicians in the US. It has also signed its first major contract with a global pharmaceutical firm for large-scale clinical trial deployment.